CN

Centene Corporation

CNCHealthcareNASDAQ

Healthcare Plans · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$194.78B
+19.4% YoY
Net Income
-$6.67B
-301.9% YoY
EBITDA
-$4.78B
-177.0% YoY
Free Cash Flow
$9.64B

Scan Results

Daily timeframe
8 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Positive CrossoverHistogram +0.0744, positive momentum
Aug 24 MACD Negative CrossoverHistogram -0.1121, negative momentum
About Centene Corporation

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. The $33.12B market capitalization puts CNC squarely in large-cap range for its industry. It operates through four segments: Medicaid, Medicare, Commercial, and Other.

Where CNC stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, CNC finished 27.08% above its 150-day moving average ($52.99) and 34.60% above its 200-day moving average ($50.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CNC overbought or oversold?

At the September 3, 2026 close, CNC's RSI(14) was 55.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$33.12B
Fwd P/E12.62
EPS$-10.36
Beta1.11
52W Change+115.8%
ROE-20.4%
Analysis

The balance sheet looks solid with $27.06B in cash comfortably exceeding the $16.10B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $9.64B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -20.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $144.55B (2022) to $194.78B (2025), reflecting a 35% increase over the period.

As with any equity investment, CNC carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing CNC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms